Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
typhoid Vi polysaccharide vaccine
- Development stage
- Unknown
- Lead developer
- Finlay Vaccine Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
vax-TyVi is a Vi polysaccharide vaccine developed by the Finlay Vaccine Institute for the prevention of typhoid fever. The vaccine is composed of the purified Vi capsular polysaccharide antigen extracted from *Salmonella enterica* serovar Typhi. Upon administration, it induces a T-cell independent immune response, stimulating the production of specific IgG antibodies against the Vi antigen, which provides protective immunity against infection. vax-TyVi is approved for use in adults and children (typically over two years of age) who are at risk of typhoid fever, particularly in endemic regions or for travelers.
- Brand names
- vax-TyVi
- Other names
- vax-TyVi vaccineFinlay typhoid vaccineTyphoid Vi polysaccharide vaccine
02
Targets
Vi polysaccharide-specific B-cell receptorVi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on typhoid Vi polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on typhoid Vi polysaccharide vaccine.